United Kingdom

People: CytomX Therapeutics Inc (CTMX.OQ)

CTMX.OQ on NASDAQ Stock Exchange Global Select Market

16 Aug 2019
Change (% chg)

$0.27 (+2.98%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Meyers, James 

Mr. James Robert Meyers is Independent Director of the company. Mr. Meyers has served as a member of our Board since December 2018. Mr. Meyers has served as a Senior Advisor to Gilead Sciences since his retirement from Gilead in February 2018. Prior to his advisory role, Mr. Meyers most recently served as Gilead’s Executive Vice President of Worldwide Commercial Operations, where he was responsible for all commercial activities including pricing and market access in North America, Europe, Middle East, Australia and Japan. Over his 22-year career at Gilead, Mr. Meyers led some of the most important and successful product launches in the history of the biopharmaceutical industry, most notably in the therapeutic areas of HCV and HIV. Prior to joining Gilead, Mr. Meyers held positions of increasing responsibility in sales, training, marketing and management with Zeneca Pharmaceuticals and Astra USA. Mr. Meyers currently serves on the Board of Arbutus Biopharma Corporation, a public biopharmaceutical company. Mr. Meyers holds a B.S. in Economics from Boston College. We believe that Mr. Meyers is qualified to serve on our Board due to his worldwide commercial leadership experience within the biotechnology industry.

Basic Compensation

Total Annual Compensation, USD 52,500
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 201,036
Fiscal Year Total, USD 253,536

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Sean McCarthy


Lloyd Rowland


Nick Galli


W. Michael Kavanaugh


Rachel Humphrey


Matthew Young

As Of  31 Dec 2018